- Company
- Dong-A ST finished Abbvie’s ₩48 billion down payment
- by Lee, Seok-Jun Jan 17, 2020 06:24am
- Dong-A ST completed a 36-month split recognition of the Abbvie technology export contract of $40 million (about &8361;48 billion). The 36 months is a period in which the two companies are considering the selection of pipelines. In other words, the preclinical study has countdown on the assumption that the pipeline has been successfully deriv
- Company
- BTX market new comers not bothered by legal dispute
- by Kim, Jin-Gu Jan 17, 2020 06:22am
- The Korean botulinum toxin market competition is reaching the peak. While the toxin strain related legal dispute has not yet been fully resolved, more and more companies are latching on to the market. Bio ventures, on top of the large and small-and-medium companies, have announced their plan to join the over-heated competition. On Jan
- Company
- Mabthera anticipating indication on pediatric polyangiitis
- by Eo, Yun-Ho Jan 16, 2020 03:07pm
- Pharmaceutical industry is expecting anticancer treatment Mabthera to get indicated for treating pediatric patients in Korea. The industry source reported Roche Korea has submitted an indication expansion application to Ministry of Food and Drug Safety (MFDS) for Mabthera (rituximab) to treat 2-year-old and older pediatric patient with g
- Company
- Pfizer's Novasc 10mg packaging will change to 28 tablets
- by Jung, Hye-Jin Jan 16, 2020 06:07am
- Pfizer's Novasc 10mg packaging unit will change from 30 tablets to 28 tablets. In addition, many drugs, including Bayer's antibiotic Avelox and Samjin Pharm's Gelma suspension, were sold out. According to the wholesale industry on the 14th, 30 tablets of Novask tablet 10mg tablet of Korean Pfizer will be discontinued and 28 tablets packagi
- Company
- Zejula indicated for late-line therapy on ovarian cancer
- by Eo, Yun-Ho Jan 16, 2020 06:06am
- Anticancer treatment Zejula is now available for a monotherapy prescription on patient with ovarian cancer, who has been treated with fourth-line or later treatment. Takeda Pharmaceuticals Korea (CEO Moon Hee-seok) official stated Ministry of Food and Drug Safety (MFDS) has additionally indicated Zejula’s (niraparib) on Dec. 24 for trea
- Company
- Recommending ezetimibe, “The lower the LDL-C, the better”
- by Eo, Yun-Ho Jan 15, 2020 06:30am
- With robust evidences of efficacy, ezetimibe is now one of major options for treating dyslipidemia. “The lower the better.” The result of clinical trial IMPROVE-IT, with the slogan claiming the lower the low-density lipoprotein cholesterol (LDL-C) is the better the health benefit, earned its recognition when it was announced in 2015. N
- Company
- Reimbursed ALL new drug Besponsa lands code at Big 5 fast
- by Eo, Yun-Ho Jan 14, 2020 06:29am
- After the green light from Korean health authority, the reimbursed Besponsa (inotuzumab) injection has quickly found its position on general hospitals’ prescription code list. According to pharmaceutical industry sources, an antibody-drug conjugate (ADC) prescribed for acute lymphoblastic leukemia (ALL), Besponsa injection has been list
- Company
- Tae-han Kim, CEO of Samsung BioLogics, attends JP Morgan
- by Lee, Seok-Jun Jan 13, 2020 06:27am
- Samsung BioLogics will present the main event space (Grand Ballroom) for two consecutive years at the JP Morgan Healthcare Conference. It is the first Korean company to make a main event space presentation. President Tae-han Kim makes a presentation by himself. Kim's attendance at the JP Morgan conference was unclear due to the prosecution's
- Company
- Hana secured copyright for anesthetic drugs in 6 countries
- by Lee, Seok-Jun Jan 13, 2020 06:26am
- Hana Pharm Co. announced on the 9th that it signed an exclusive contract with six countries in Southeast Asia for anesthetic drug, Remimazolam. Remimazolam is a new anesthetic drug that is considered to be a Propofol alternative. After finishing phases III in each country, they are getting global approval for Japan, USA and Europe. The origin
- Company
- Sanofi recruits 4943 patients in three clinical trials
- by Chon, Seung-Hyun Jan 13, 2020 06:22am
- Hanmi Pharmaceutical's new technology, "Efpeglenatide", exported to Sanofi, continues commercializing smoothly.. Three cases were recruited out of five phase III trials. In three clinical trials, a total of 4943 patients were recruited, accumulating the scientific evidence to prove the competitiveness of Efpeglenatide. According to Clinica
